Literature DB >> 26722301

HO-1, RET and PML as possible markers for risk stratification of acute myelocytic leukemia and prognostic evaluation.

Meisheng Yu1, Jishi Wang2, Dan Ma3, Shuya Chen1, Xiaojing Lin1, Qin Fang4, Nana Zhe1.   

Abstract

Heme oxygenase-1 (HO-1) is an inducible isoform of HO that is activated in response to oxidative stress and has anti-apoptotic and pro-proliferative effects on leukemia cells. RET, a tyrosine kinase receptor; its expression levels are associated with the differentiation degree of acute myelocytic leukemia (AML) cells. The promyelocytic leukemia (PML) gene inhibits cell proliferation and tumor growth, participates in the differentiation of hematopoietic progenitor cells and induces cell apoptosis. However, the association between the expression levels of HO-1, RET and PML genes and the risk stratification of AML and prognosis have not previously been reported. In the present study, HO-1 was expressed in the human AML Kasumi-1, HL-60 and THP-1 cell lines, and HO-1 expression was regulated by Hemin (20 µmol/l) and ZnPPIX (10 µmol/l). Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis demonstrated that expression of RET and PML were positively and negatively correlated with HO-1 expression, respectively. Bone marrow samples (18 favorable, 55 intermediate, 15 adverse and 2 unknown karyotype AML cases and 20 healthy donors) were collected from 90 randomly selected AML patients upon their first visit. The mRNA and protein expression of HO-1, RET and PML in samples was detected by RT-qPCR and western blot analysis. At the mRNA level, the adverse group expressed significantly higher levels of HO-1 and RET compared with the levels in the favorable and normal groups. The PML mRNA expression levels in adverse patient samples was lower compared with those of the intermediate group and favorable group. Western blot analysis demonstrated that the expression levels of HO-1, RET and PML proteins in all risk groups exhibited the same pattern of expression as was observed for the mRNA levels. The overall survival and relapse-free survival rates were shortest in AML patients with high HO-1 expression (Kaplan-Meier; log-rank, P<0.01). The results of the present study therefore indicate that HO-1, RET and PML may be critical in the risk-stratification and prognosis of AML. However, additional samples and clinical data should be collected and analyzed in order to provide stronger evidence for this hypothesis.

Entities:  

Keywords:  AML; HO-1; PML; RET; prognosis; risk stratification

Year:  2015        PMID: 26722301      PMCID: PMC4665859          DOI: 10.3892/ol.2015.3644

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  33 in total

1.  Expression of heme oxygenase-1 in human leukemic cells and its regulation by transcriptional repressor Bach1.

Authors:  Takuya Miyazaki; Yohei Kirino; Mitsuhiro Takeno; Sei Samukawa; Maasa Hama; Masatsugu Tanaka; Satoshi Yamaji; Atsuhisa Ueda; Naoto Tomita; Hiroyuki Fujita; Yoshiaki Ishigatsubo
Journal:  Cancer Sci       Date:  2010-03-02       Impact factor: 6.716

2.  Role of PML in cell growth and the retinoic acid pathway.

Authors:  Z G Wang; L Delva; M Gaboli; R Rivi; M Giorgio; C Cordon-Cardo; F Grosveld; P P Pandolfi
Journal:  Science       Date:  1998-03-06       Impact factor: 47.728

3.  Nrf2 responses and the therapeutic selectivity of electrophilic compounds in chronic lymphocytic leukemia.

Authors:  Raymond P Wu; Tomoko Hayashi; Howard B Cottam; Guangyi Jin; Shiyin Yao; Christina C N Wu; Michael D Rosenbach; Maripat Corr; Richard B Schwab; Dennis A Carson
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-05       Impact factor: 11.205

4.  Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma.

Authors:  Minjing Zou; Essa Y Baitei; Ali S Alzahrani; Faisal S BinHumaid; Dania Alkhafaji; Roua A Al-Rijjal; Brian F Meyer; Yufei Shi
Journal:  Thyroid       Date:  2014-06-10       Impact factor: 6.568

5.  Integrative prognostic risk score in acute myeloid leukemia with normal karyotype.

Authors:  Frederik Damm; Michael Heuser; Michael Morgan; Katharina Wagner; Kerstin Görlich; Anika Grosshennig; Iyas Hamwi; Felicitas Thol; Ewa Surdziel; Walter Fiedler; Michael Lübbert; Lothar Kanz; Christoph Reuter; Gerhard Heil; Ruud Delwel; Bob Löwenberg; Peter J M Valk; Jürgen Krauter; Arnold Ganser
Journal:  Blood       Date:  2011-03-03       Impact factor: 22.113

6.  Inhibition of heme oxygenase-1 increases responsiveness of pancreatic cancer cells to anticancer treatment.

Authors:  Pascal O Berberat; Zilvinas Dambrauskas; Antanas Gulbinas; Thomas Giese; Nathalia Giese; Beat Künzli; Frank Autschbach; Stefen Meuer; Markus W Büchler; Helmut Friess
Journal:  Clin Cancer Res       Date:  2005-05-15       Impact factor: 12.531

7.  HO-1 underlies resistance of AML cells to TNF-induced apoptosis.

Authors:  Stuart A Rushworth; David J MacEwan
Journal:  Blood       Date:  2008-01-17       Impact factor: 22.113

8.  Identification of heme oxygenase-1 as a novel BCR/ABL-dependent survival factor in chronic myeloid leukemia.

Authors:  Matthias Mayerhofer; Stefan Florian; Maria-Theresa Krauth; Karl J Aichberger; Martin Bilban; Rodrig Marculescu; Dieter Printz; Gerhard Fritsch; Oswald Wagner; Edgar Selzer; Wolfgang R Sperr; Peter Valent; Christian Sillaber
Journal:  Cancer Res       Date:  2004-05-01       Impact factor: 12.701

9.  Identification of novel molecular markers for prognosis estimation of acute myeloid leukemia: over-expression of PDCD7, FIS1 and Ang2 may indicate poor prognosis in pretreatment patients with acute myeloid leukemia.

Authors:  Yiming Tian; Zoufang Huang; Zhixiang Wang; Changxin Yin; Lanlan Zhou; Lingxiu Zhang; Kaikai Huang; Hongsheng Zhou; Xuejie Jiang; Jinming Li; Libin Liao; Mo Yang; Fanyi Meng
Journal:  PLoS One       Date:  2014-01-08       Impact factor: 3.240

10.  PML suppresses oncogenic transformation of NIH/3T3 cells by activated neu.

Authors:  J H Liu; Z M Mu; K S Chang
Journal:  J Exp Med       Date:  1995-06-01       Impact factor: 14.307

View more
  2 in total

1.  Gab2 deficiency prevents Flt3-ITD driven acute myeloid leukemia in vivo.

Authors:  Corinna Spohr; Teresa Poggio; Geoffroy Andrieux; Katharina Schönberger; Nina Cabezas-Wallscheid; Melanie Boerries; Sebastian Halbach; Anna L Illert; Tilman Brummer
Journal:  Leukemia       Date:  2021-12-13       Impact factor: 11.528

Review 2.  Clinical Significance of Heme Oxygenase 1 in Tumor Progression.

Authors:  Mariapaola Nitti; Caterina Ivaldo; Nicola Traverso; Anna Lisa Furfaro
Journal:  Antioxidants (Basel)       Date:  2021-05-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.